Retatrutide: the “triple G” next in line

What retatrutide is

Retatrutide (developmental code LY3437943) is an investigational once-weekly injectable from Eli Lilly. It is a single molecule that activates three metabolic hormone receptors at once — GIP, GLP-1, and glucagon — so it is called a "triple agonist." The GLP-1/GIP arms are thought to curb appetite and improve blood-sugar handling; the added glucagon arm is thought to raise energy expenditure, which is what distinguishes it from drugs already on the market.

What the trials showed

Grounded in the Phase 2 trial: Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," N Engl J Med 2023;389(6):514-526 (PMID 37366315; NCT04881760; Lilly-funded). Verified exactly against PubMed and the ClinicalTrials.gov API: double-blind, randomized, placebo-controlled, 338 adults with obesity, weekly injection for 48 weeks at 1/4/8/12 mg vs placebo. Least-squares mean body-weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg highest dose) vs −2.1% placebo. The widely quoted "~24%" is specifically the 12 mg group average, NOT an all-comers average and NOT a guaranteed individual result. Hedges required and present: this is a mid-stage (~11-month, few-hundred-person) trial, weight was still trending down at 48 weeks, it was not powered for rare or long-term safety signals, and Phase 2 results do not always hold at Phase 3 scale. Phase 3 TRIUMPH trials (e.g., NCT05929066, 2,335 participants, listed COMPLETED) exist, but no peer-reviewed Phase 3 efficacy percentage is quoted — treat any Phase 3 number circulating online as unconfirmed until published.

Frequently asked

Is retatrutide FDA-approved or available?

NOT FDA-approved and NOT available by prescription — it is still an experimental drug in clinical trials, so no pharmacy, telehealth clinic, or "men's health" site can legally sell real, approved retatrutide because no such approved product exists. WARNING: "retatrutide"/"reta" vials sold online as powders or pre-mixed peptides (often labeled "for research purposes" or "not for human consumption") are unapproved, unregulated grey-market research chemicals with unknown purity, dose, and contents. Do not buy them and do not inject them — there is no sterility guarantee, no quality control, and no one accountable if you are harmed. The legitimate path is a registered clinical trial under medical supervision, not a website. Verified against ClinicalTrials.gov: Lilly runs a Phase 1-3 program including a completed Phase 2 (NCT04881760), Phase 3 TRIUMPH obesity trials, TRIUMPH-Outcomes CV/kidney trial (NCT06383390), and a "pre-approval expanded access" record (NCT07629401) that by definition exists only because the drug is not yet approved.

How much weight did people lose on retatrutide in trials?

Grounded in the Phase 2 trial: Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," N Engl J Med 2023;389(6):514-526 (PMID 37366315; NCT04881760; Lilly-funded). Verified exactly against PubMed and the ClinicalTrials.gov API: double-blind, randomized, placebo-controlled, 338 adults with obesity, weekly injection for 48 weeks at 1/4/8/12 mg vs placebo. Least-squares mean body-weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg highest dose) vs −2.1% placebo. The widely quoted "~24%" is specifically the 12 mg group average, NOT an all-comers average and NOT a guaranteed individual result. Hedges required and present: this is a mid-stage (~11-month, few-hundred-person) trial, weight was still trending down at 48 weeks, it was not powered for rare or long-term safety signals, and Phase 2 results do not always hold at Phase 3 scale. Phase 3 TRIUMPH trials (e.g., NCT05929066, 2,335 participants, listed COMPLETED) exist, but no peer-reviewed Phase 3 efficacy percentage is quoted — treat any Phase 3 number circulating online as unconfirmed until published.

How does retatrutide compare to Ozempic?

Mechanism comparison is correct: Ozempic = semaglutide, a single-target GLP-1 agonist (approved for type 2 diabetes; same molecule at higher dose is Wegovy for weight). Tirzepatide (Mounjaro/Zepbound) is a dual GIP+GLP-1 agonist. Retatrutide is a triple GIP+GLP-1+glucagon agonist. On paper retatrutide's top-line Phase 2 result (~−24% at 48 weeks, highest dose) looks larger than commonly cited figures for semaglutide 2.4 mg (~15% at 68 weeks) and tirzepatide (~20-21% at 72 weeks) — but these are CROSS-TRIAL comparisons with different participants, durations, doses, and designs, NOT head-to-head. You cannot conclude "retatrutide beats Ozempic by X%." Lilly is running actual head-to-head studies (reta vs tirzepatide NCT06662383; reta vs semaglutide NCT06260722, both verified on ClinicalTrials.gov), and those results — not cross-trial math — will settle it. Also: two of the three drugs are FDA-approved and prescribable today; retatrutide is not.

Is retatrutide safe?

In the Phase 2 trial the most common side effects were gastrointestinal (nausea, vomiting, diarrhea, constipation) — dose-related, mostly mild-to-moderate, and reduced by starting low and titrating up, the same tolerability pattern as other GLP-1-class drugs. Dose-dependent heart-rate increases peaked around 24 weeks then declined, and because the glucagon component affects glucose/metabolic parameters, labs are monitored closely. Long-term safety is UNKNOWN: Phase 2 was only 48 weeks in a few hundred people, so rare adverse events, multi-year effects, effects in people with other conditions, and post-discontinuation weight regain are all still being studied. This uncertainty is exactly why it is not yet approved and why self-experimenting with grey-market "reta" — unproven drug, unverified dose, unverified source, no medical monitoring — is reckless.